PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Internal administration of M. arundinacea starch (4 g TID for 30 days) was found to be highly effective in treating Amlapitta [PMID:22048544]
The addition of 100 gm of arrowroot powder to enteral formula feeds was evaluated for safety and GI tolerance regarding diarrhea, vomiting, and abdominal distension [PMID:42147699]
Methanolic extract of leaves inhibited diarrheal episodes by 42.67% to 57.75% in rats [PMID:26346095]
Dietary fibers from M. arundinacea rhizomes prevented type 2 diabetes in mice fed a high-fat diet [PMID:41607423]
Dietary M. arundinacea was studied for chemopreventive effects against DMBA-induced mammary cancer in rats via regulation of autophagy [PMID:35345372]
Safety & adverse effects
Dosage & administration
Evidence summary
PubMed sources
- 1.PMID: 40382045 (2025) — Exploring nutritional and bioactive properties of Maranta arundinacea L.: An unconventional food plant. · Food research international (Ottawa, Ont.)
- 2.PMID: 37810033 (2023) — Characterization of arrowroot (Maranta arundinacea) starch as a potential starch source for the food industry. · Heliyon
- 3.PMID: 22038480 (2012) — Evaluation of immunostimulatory effect of the arrowroot (Maranta arundinacea. L) in vitro and in vivo. · Cytotechnology
- 4.PMID: 42147699 (2026) — Gastrointestinal Tolerance to Maranta arundinacea (Arrowroot) Powder Added to Formula Feeds in Intensive Care Unit Patients: A Nonrandomized Controlled Quasi-experimental Trial. · Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine
- 5.PMID: 35345372